1. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC, National Academies, 1997.
2. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 42:S1-S201, 2003 (suppl 3)
3. Mensah GA: Refining strategies for the prevention and con¬trol of hypertension and related complications. Ethn Dis 1999;9:327-332.
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA,
et al The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blo¬od Pressure: The JNC 7 report. JAMA 2003;289:2560-2572.
5. Major cardiovascular events in hypertensive patients rando¬mized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial
(ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000;283:1967-1975.
6. Appel LJ: The verdict from ALLHAT—Thiazide diuretics are the preferred initial therapy for hypertension. JAMA
2002;288:3039-3042.
7. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, et al: Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foun¬dation Task Force on Cardiovascular Disease. Am J Kidney
Dis 1998;32:853-906.
8. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, et
al: Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundati¬on Hypertension and Diabetes Executive Committees Wor¬king Group. Am J Kidney Dis 2000;36:646-661.
9. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL,
Ford CE, Shulman NB, Stamler J: Blood pressure and end-sta¬ge renal disease in men. N Engl J Med 1996;334:13-18.
10. K/DOQI clinical practice guidelines for chronic kidney disea¬se: Evaluation, classification, and stratification. Kidney Disea¬se Outcome Quality Initiative. Am J Kidney Dis 2002(suppl 2);39:S1-S266.
11. Keane WF, Eknoyan G: Proteinuria, albuminuria, risk, assess¬ment, detection, elimination (PARADE): A position paper of the National Kidney Foundation. Am J Kidney Dis
1999;33:1004-1010.
12. Major outcomes in high-risk hypertensive patients randomi¬zed to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
JAMA 2002;288:2981-2997.
13. Reubi FC, Cottier PT: Effect of reduced glomerular filtration rate on responsiveness to chlorothiazide and mercurial diure¬tics. Circulation 1961;23:200.
14. Rajagopalan S, Pitt B: Aldosterone antagonists in the treat¬ment of hypertension and target organ damage. Curr Hyper-
tens Rep 2001;3:240-248.
15. Pollare T, Lithell H, Morlin C, Prantare H, Hvarfner A, Ljung-hall S: Metabolic effects of diltiazem and atenolol: Results from a randomized, double-blind study with parallel groups.
J Hypertens 1989;7:551-559.
16. 309. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD: He¬alth outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analy-
sis. JAMA 1997;277:739-745.
17. Moser M, Frishman W: Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients. Am J Hypertens 1998;11:15S-22S.
18. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9-13.
19. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagste-in F, et al: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Interventi¬on Trial in congestive heart failure (MERIT-HF). MERIT-HF
Study Group. JAMA 2000;283:1295-1302.
20. Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS: The
relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA
1990;263:1653-1657.
21. Houston MC: Abrupt cessation of treatment in hypertension: Consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome. Am He¬art J 1981;102:415-430.
22. Effects of enalapril on mortality in severe congestive heart fa¬ilure. Results of the Cooperative North Scandinavian Enalap-ril Survival Study (CONSENSUS). The CONSENSUS Trial
Study Group. N Engl J Med 1987;316:1429-1435.
23. Ambrosioni E, Borghi C, Magnani B: The effect of the angi-otensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survi¬val of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332:80-85.
24. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 275:1507-1513,
1996
25. Effects of ramipril on cardiovascular and microvascular out¬comes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-259.
26. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA et al, Se¬cond Australian National Blood Pressure Study Group: A comparison of outcomes with angiotensin-converting—enz-yme inhibitors and diuretics for hypertension in the elderly.
N Engl J Med 2003;348:583-592.
27. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, et al: Effect of angiotensin-converting-enzyme inhibition com¬pared with conventional therapy on cardiovascular morbidity
Official Journal of the Turkish Society of Nephrology / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
61
Principles of Antihypertensive Therapy in Chronic Kidney Disease
and mortality in hypertension: The Captopril Prevention Pro¬ject (CAPPP) randomised trial. Lancet 1999;353:611-616.
28. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, et al: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against ate-
nolol. Lancet 2002;359:1004-1010.
29. Shotan A, Widerhorn J, Hurst A, Elkayam U: Risks of angi-otensin-converting enzyme inhibition during pregnancy: Ex¬perimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 1994;96:451-456.
30. Abernethy DR, Schwartz JB: Calcium-antagonist drugs. N
Engl J Med 1999;341:1447-1457.
31. Bakris GL, Barnhill BW, Sadler R: Treatment of arterial hyper¬tension in diabetic humans: Importance of therapeutic selec¬tion. Kidney Int 1992;41:912-919.
32. 359. Bohlen L, de Courts M, Weidmann P: Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens
1994;7:84S-92S.
33. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial
II—DAVIT II). Am J Cardiol 1990;66:779-785.
34. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Ko-
wey P, et al: A calcium antagonist vs a non-calcium antago¬nist hypertension treatment strategy for patients with coro¬nary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003;290:2805-2816.
35. Black HR, Elliott WJ, Grandits G, Grambsh P, Lucente T, et
al: Principal results of the Controlled Onset Verapamil Inves¬tigation of Cardiovascular End Points (CONVINCE) trial. JA¬MA 2003;289:2073-2082.
36. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lind-holm LH, et al: Randomised trial of effects of calcium anta¬gonists compared with diuretics and beta-blockers on cardi¬ovascular morbidity and mortality in hypertension: The Nor¬dic Diltiazem (NORDIL) study. Lancet 2000;356:359-365.
37. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting cal¬cium-channel blocker or diuretic in the International Nifedi-pine GITS study: Intervention as a Goal in Hypertension Tre¬atment (INSIGHT). Lancet 2000;356:366-372.
38. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strol-
lo G, Strollo F: Outcome results of the Fosinopril Versus Am-lodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care
1998;21:597-603.
39. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birken-
hager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE,
Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Ro-dicio JL, Tuomilehto J, Zanchetti A: Randomised double-blind comparison of placebo and active treatment for older pati¬ents with isolated systolic hypertension. The Systolic Hyper¬tension in Europe (Syst-Eur) Trial Investigators. Lancet
1997;350:757-764.
40. Wang JG, Staessen JA, Gong L, Liu L: Chinese trial on isola¬ted systolic hypertension in the elderly. Systolic Hypertensi¬on in China (Syst-China) Collaborative Group. Arch Intern
Med 2000;160:211-220.
41. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D,
Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects
of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hyperten¬sion Optimal Treatment (HOT) randomised trial. HOT Study
Group. Lancet 1998;351:1755-1762.
42. Oster Jr, Epstein M: Use of centrally acting sympatholytic agents in the management of hypertension. Arch Intern Med
1991;151:1638-1644.
43. Vanholder R, Carpentier J, Schurgers M, Clement DL: Rebo¬und phenomenon during gradual withdrawal of clonidine.
BMJ 1977;1:1138.
44. Khoury AF, Kaplan NM: Alpha-blocker therapy of hyperten¬sion. An unfulfilled promise. JAMA 1991;266:394-398.
45. Sica DA, Gehr TW: Direct vasodilators and their role in hypertension management: Minoxidil. J Clin Hypertens
2001;3:110-114.
46. Zarate A, Gelfand MC, Horton JD, Winchester JF, Gottlieb MJ,
Lazarus JM, Schreiner GE: Pericardial effusion associated with minoxidil therapy in dialyzed patients. Int J Artif Organs
1980;3:15-17.
47. Julien J, Dufloux MA, Prasquier R, Chatellier G, Menard D, Plouin PF, Menard J, Corvol P: Effects of captopril and mino-xidil on left ventricular hypertrophy in resistant hypertensive patients: A 6 month double-blind comparison. J Am Coll Car-
diol 1990;16:137-142.
48. 383. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Pe¬rez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N
Engl J Med 1999;341:709-717.
49. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brig-hetti G, Marino P, Zardini P: Long-term, dose-dependent ef¬fects of spironolactone on left ventricular function and exer¬cise tolerance in patients with chronic heart failure. J Am Coll
Cardiol 2002;40:304-310.
50. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a se¬lective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med
2003;348:1309-1321.
Thank you for copying data from http://www.arastirmax.com
